Eric D Hamlett

List of Publications by Year
in descending order

22	727	759233 12	794594 19
papers	citations	h-index	g-index

22	22	22	1500
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Wnt1/Î²catenin injury response activates the epicardium and cardiac fibroblasts to promote cardiac repair. EMBO Journal, 2012, 31, 429-442.	7.8	252
2	Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome. Alzheimer's and Dementia, 2017, 13, 541-549.	0.8	94
3	Exosomal biomarkers in Down syndrome and Alzheimer's disease. Free Radical Biology and Medicine, 2018, 114, 110-121.	2.9	64
4	Designer Receptors Enhance Memory in a Mouse Model of Down Syndrome. Journal of Neuroscience, 2015, 35, 1343-1353.	3.6	61
5	Neuronally derived extracellular vesicles: an emerging tool for understanding Alzheimerâ€™s disease. Molecular Neurodegeneration, 2019, 14, 22.	10.8	51
6	Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome. Current Alzheimer Research, 2015, 13, 35-52.	1.4	41
7	Alpha-lipoic acid supplementation protects enzymes from damage by nitrosative and oxidative stress. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 36-45.	2.4	28
8	RvE1 treatment prevents memory loss and neuroinflammation in the Ts65Dn mouse model of Down syndrome. Glia, 2020, 68, 1347-1360.	4.9	24
9	Diggināˆ² on U(biquitin): A Novel Method for the Identification of Physiological E3 Ubiquitin Ligase Substrates. Cell Biochemistry and Biophysics, 2013, 67, 127-138.	1.8	15
10	Exosome release and cargo in Down syndrome. Developmental Neurobiology, 2019, 79, 639-655.	3.0	15
11	Evidence of altered age-related brain cytoarchitecture in mouse models of down syndrome: a diffusional kurtosis imaging study. Magnetic Resonance Imaging, 2015, 33, 437-447.	1.8	14
12	Suppression of Fli-1 protects against pericyte loss and cognitive deficits in Alzheimer's disease. Molecular Therapy, 2022, 30, 1451-1464.	8.2	14
13	High-Accuracy Peptide Mass Fingerprinting Using Peak Intensity Data with Machine Learning. Journal of Proteome Research, 2008, 7, 62-69.	3.7	12
14	Small Neuron-Derived Extracellular Vesicles from Individuals with Down Syndrome Propagate Tau Pathology in the Wildtype Mouse Brain. Journal of Clinical Medicine, 2021, 10, 3931.	2.4	10
15	Inhibitory designer receptors aggravate memory loss in a mouse model of down syndrome. Neurobiology of Disease, 2020, 134, 104616.	4.4	9
16	Chronic cannabis smoking-enriched oral pathobiont drives behavioral changes, macrophage infiltration, and increases Î²-amyloid protein production in the brain. EBioMedicine, 2021, 74, 103701.	6.1	8
17	Building the Future Therapies for Down Syndrome: The Third International Conference of the T21 Research Society. Molecular Syndromology, 2021, 12, 202-218.	0.8	6
18	Greater Diffusion Restriction in White Matter in Preclinical Alzheimer Disease. Annals of Neurology, 2022, , .	5.3	6

#	Article	IF	Citations
19	Proteomic analysis of mice expressing human <scp>A</scp>po<scp>E</scp> demonstrates no differences in global protein solubility between <scp>APOE</scp> 3 and <scp>APOE</scp> 4 young mice. Electrophoresis, 2012, 33, 3745-3755.	2.4	3
20	Identification and Characterization of Protein Posttranslational Modifications by Differential Fluorescent Labeling. Neuromethods, 2015, , 243-262.	0.3	0
21	The role of calbindinâ€D28k in a mouse model of Down syndromeâ€related Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e042295.	0.8	0
22	Fluid biomarkers for Alzheimer's disease in Down syndrome: Current status and novel trends. , 2022, , 97-128.		0